CY1121780T1 - Γενετικως κατασκευασμενα πολυπεπτιδια που εχουν ενισχυμενη διαρκεια δρασης και μειωμενη ανοσογονικοτητα - Google Patents

Γενετικως κατασκευασμενα πολυπεπτιδια που εχουν ενισχυμενη διαρκεια δρασης και μειωμενη ανοσογονικοτητα

Info

Publication number
CY1121780T1
CY1121780T1 CY20191100661T CY191100661T CY1121780T1 CY 1121780 T1 CY1121780 T1 CY 1121780T1 CY 20191100661 T CY20191100661 T CY 20191100661T CY 191100661 T CY191100661 T CY 191100661T CY 1121780 T1 CY1121780 T1 CY 1121780T1
Authority
CY
Cyprus
Prior art keywords
compounds
disease
action
genetically engineered
engineered polypeptides
Prior art date
Application number
CY20191100661T
Other languages
English (en)
Inventor
Mary Erickson
David C Litzinger
Soumitra S. Ghosh
Zijian Guo
Caroline Ekblad
Jonathan David Roth
Original Assignee
Aegerion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegerion Pharmaceuticals, Inc. filed Critical Aegerion Pharmaceuticals, Inc.
Publication of CY1121780T1 publication Critical patent/CY1121780T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)

Abstract

Παρέχονται ενώσεις που έχουν inter alia καλή διάρκεια δράσης, υψηλή ισχύ ή/και κατάλληλες αγωγές δοσολόγησης, που συμπεριλαμβάνουν χορήγηση μιας φοράς εβδομαδιαίως. Οι ενώσεις είναι γενετικώς κατασκευασμένα πολυπεπτίδια που ενσωματώνουν πεδίο σύνδεσης αλβουμίνης σε συνδυασμό με ένα ή περισσότερα βιολογικώς δραστικά πολυπεπτίδια. Επίσης, παρεχόμενες είναι φαρμακευτικές συνθέσεις και μέθοδοι θεραπείας για ασθένειες και διαταραχές που συμπεριλαμβάνουν λιποδυστροφία, δυσλιπιδαιμία, υπερλιπιδαιμία, υπερβολικό βάρος, παχυσαρκία, υποθαλαμική αμηνόρροια, ασθένεια Alzheimer, ανεπάρκεια λεπτίνης, λιπαρού ήπατος ασθένεια ή διαβήτη (που συμπεριλαμβάνει τύπου I και τύπου II). Επιπρόσθετες ασθένειες και διαταραχές οι οποίες μπορεί να θεραπεύονται με τις ενώσεις και τις μεθόδους που περιγράφονται στο παρόν περιλαμβάνουν μη αλκοολική στεατοηπατίτιδα (NASH) και μη αλκοολική λιπαρού ήπατος ασθένεια (NAFLD), μεταβολικό σύνδρομο Χ και Ασθένεια Huntington.
CY20191100661T 2011-07-08 2019-06-26 Γενετικως κατασκευασμενα πολυπεπτιδια που εχουν ενισχυμενη διαρκεια δρασης και μειωμενη ανοσογονικοτητα CY1121780T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506001P 2011-07-08 2011-07-08
US201161540422P 2011-09-28 2011-09-28
PCT/US2012/045398 WO2013009539A1 (en) 2011-07-08 2012-07-03 Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Publications (1)

Publication Number Publication Date
CY1121780T1 true CY1121780T1 (el) 2020-07-31

Family

ID=47506411

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100661T CY1121780T1 (el) 2011-07-08 2019-06-26 Γενετικως κατασκευασμενα πολυπεπτιδια που εχουν ενισχυμενη διαρκεια δρασης και μειωμενη ανοσογονικοτητα

Country Status (9)

Country Link
US (3) US20140256621A1 (el)
EP (1) EP2729160B1 (el)
JP (2) JP6040464B2 (el)
CN (1) CN103957926B (el)
CY (1) CY1121780T1 (el)
DK (1) DK2729160T3 (el)
ES (1) ES2732475T3 (el)
PT (1) PT2729160T (el)
WO (1) WO2013009539A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CA2804002C (en) 2010-07-09 2021-07-20 Affibody Ab Albumin-binding polypeptides, fusion proteins, and compositions thereof
EP3241558B1 (en) * 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US10155792B2 (en) * 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
RU2721949C2 (ru) 2015-09-22 2020-05-25 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модифицированные цитотоксины и их терапевтическое применение
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10487121B2 (en) * 2016-01-07 2019-11-26 Navigen, Inc. D-peptide inhibitors of HIV entry and methods of use
WO2018049424A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
EP3604538A4 (en) 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
TWI815327B (zh) * 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
YU5396A (sh) 1995-01-31 1998-08-14 Eli Lilly And Company, Lilly Corporate Center Novi biološki aktivni proteini, njihove farmaceutske formulacije i postupak za njihovo dobijanje
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5840517A (en) 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
CZ416797A3 (cs) 1995-06-30 1998-06-17 Eli Lilly And Company Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
EP0956302A1 (en) 1996-09-20 1999-11-17 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
DK0954588T3 (da) 1996-12-20 2007-05-14 Amgen Inc OB fusionsprotein-sammensætninger og fremgangsmåder
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
AU6569998A (en) 1997-03-20 1998-10-12 Eli Lilly And Company Obesity protein formulations
IL133136A0 (en) 1997-06-06 2001-03-19 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US6326468B1 (en) 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
WO1999063614A1 (fr) 1998-05-29 1999-12-09 Catalysts & Chemicals Industries Co., Ltd. Procede servant a fabriquer une cellule photoelectrique et semiconducteur a l'oxyde pour cellule photoelectrique
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
EP1214351A2 (en) 1999-09-22 2002-06-19 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
JPWO2004039853A1 (ja) 2002-11-01 2006-03-02 株式会社トクヤマ 重合性組成物、その硬化体の製造法および光学物品
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2233497A3 (en) 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2009538824A (ja) 2006-03-31 2009-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
KR20090031368A (ko) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. 울혈성 심부전 치료용 조성물 및 방법
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
US20100323955A1 (en) 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CA2712606A1 (en) * 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
CA2804002C (en) 2010-07-09 2021-07-20 Affibody Ab Albumin-binding polypeptides, fusion proteins, and compositions thereof
EP3241558B1 (en) * 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
CN103370083B (zh) 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
DK2729160T3 (da) * 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet

Also Published As

Publication number Publication date
US9879063B2 (en) 2018-01-30
EP2729160A1 (en) 2014-05-14
EP2729160B1 (en) 2019-03-27
US20140256621A1 (en) 2014-09-11
ES2732475T3 (es) 2019-11-22
US20160207974A1 (en) 2016-07-21
CN103957926A (zh) 2014-07-30
JP2014528917A (ja) 2014-10-30
PT2729160T (pt) 2019-07-08
WO2013009539A8 (en) 2014-02-27
EP2729160A4 (en) 2015-01-21
CN103957926B (zh) 2018-07-03
JP2016183180A (ja) 2016-10-20
JP6618854B2 (ja) 2019-12-11
US20180305430A1 (en) 2018-10-25
WO2013009539A1 (en) 2013-01-17
JP6040464B2 (ja) 2016-12-07
DK2729160T3 (da) 2019-07-01

Similar Documents

Publication Publication Date Title
CY1121780T1 (el) Γενετικως κατασκευασμενα πολυπεπτιδια που εχουν ενισχυμενη διαρκεια δρασης και μειωμενη ανοσογονικοτητα
CY1119498T1 (el) Συντηγμενα πολυπεπτιδια λεπτινης-abd με ενισχυμενη διαρκεια δρασης
CY1123591T1 (el) Ενωσεις γλυκαγονης και συναγωνιστων glp-1
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
CY1119376T1 (el) Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BRPI0317376B8 (pt) proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
MX345245B (es) Polipeptidos manipulados que tienen duracion de accion incrementada.
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
EA201201120A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b
NZ725131A (en) Tubulysin derivatives
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
IN2015DN00376A (el)
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.